The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2021Hypoxia (Limiting Oxygen Levels) as a Novel Treatment for Parkinson’s Disease
Study Rationale:
Many anecdotes suggest that people with Parkinson’s disease (PD) can experience a marked improvement in symptoms when they travel to the mountains or during flights at high altitude... -
Biosample Use Program, 2021Evaluating Neurotoxic Metabolites as Biomarkers of Parkinson’s Progression
Study Rationale:
Individuals with Parkinson’s disease (PD) show elevated markers of inflammation in their brains, cerebrospinal fluid and blood. We think that inflammation drives the worsening of... -
Target Advancement Program, 2021SCARB2 as a Potential Target in Parkinson’s Disease
Study Rationale:
Mutations in GBA, a gene that encodes an enzyme called glucocerebrosidase, are a common risk factor for Parkinson’s disease (PD). Inside cells, glucocerebrosidase must be escorted to... -
Target Advancement Program, 2021Targeting the Chemical Modification of DNA to Suppress Neurodegeneration in Parkinson’s Disease
Study Rationale:
Genes can be switched on or off by proteins that add and remove chemical modifications to DNA. We and others have shown that the chemical modification of genes important for... -
Target Advancement Program, 2021Modulation of Epigenetic Regulator HDAC4 as a Parkinson’s Treatment
Study Rationale:
Scientists can take skin cells from people with Parkinson’s disease (PD), turn them into stem cells, and then engineer them into dopamine neurons, the cell type lost in PD. Our... -
Therapeutic Pipeline Program, 2021Novel Inhibitors of Protein Aggregation as Potential Therapeutics for Parkinson’s Disease
Study Rationale:
The protein alpha-synuclein can aggregate in brain cells, which leads to brain cell death in Parkinson’s disease (PD). We plan to investigate a novel class of drugs — called protein...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.